Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
暂无分享,去创建一个
Augustin Ferrant | Chantal Doyen | J. Rossi | R. Bataille | B. Pégourié | B. Grosbois | I. Yakoub-Agha | J. Mary | T. Facon | J. Harousseau | C. Doyen | A. Ferrant | J. Eschard | M. Attal | F. Maloisel | P. Collet | Jean-Yves Mary | H. Eghbali | M. Wetterwald | C. Hulin | Thierry Facon | Jean-Luc Harousseau | A. Thyss | G. Lepeu | Philippe Casassus | Régis Bataille | Michel Attal | Cyrille Hulin | Marc Renaud | Laurent Voillat | Mathieu Monconduit | Antoine Thyss | L. Voillat | H. Orfeuvre | H. Maisonneuve | M. Vekemans | Philippe Collet | Marc Wetterwald | Jean-François Rossi | Hervé Maisonneuve | Brigitte Pégourie | Alain Sadoun | Véronique Dorvaux | Gérard Lepeu | Jean-Paul Eschard | Michel Blanc | Frédéric Maloisel | Hubert Orfeuvre | Isabelle Azaïs | Bruno Anglaret | Ibrahim Yakoub-Agha | Houchingue Eghbali | Marie-Christine Vekemans | Jacques Troncy | Bernard Grosbois | Jérome Jaubert | Béatrice Thielemans | J. Jaubert | B. Anglaret | M. Blanc | J. Troncy | P. Casassus | M. Renaud | M. Monconduit | V. Dorvaux | Isabelle | A. Sadoun | I. Azaïs | Marc | B. Thielemans | Grosbois | Wetterwald | Bernard | Voillat
[1] T M Grogan,et al. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[3] Mike Clarke,et al. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Miguel,et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma , 2004, British journal of haematology.
[5] B. Barlogie,et al. Primary dexamethasone treatment of multiple myeloma. , 1992, Blood.
[6] P K Andersen,et al. Conditional power calculations as an aid in the decision whether to continue a clinical trial. , 1987, Controlled clinical trials.
[7] S. Rajkumar,et al. Thalidomide Plus Dexamethasone Versus Dexamethasone Alone in Newly Diagnosed Multiple Myeloma (E1A00): Results of a Phase III Trial Coordinated by the Eastern Cooperative Oncology Group. , 2004 .
[8] M. Buyse,et al. Cancer Clinical Trials: Methods and Practice. , 1985 .
[9] M. Dimopoulos,et al. Combination therapy with interferon‐dexamethasone for newly diagnosed patients with multiple myeloma , 1993 .
[10] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[11] J. Foekens,et al. Identification of prognostic factors , 1994 .
[12] H. Wilson,et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.
[13] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[14] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[15] B. Barlogie,et al. High-dose glucocorticoid treatment of resistant myeloma. , 1986, Annals of internal medicine.